Moderna(US:MRNA) Financial Modeling Prep·2025-11-21 02:00Core Insights - Moderna, Inc. is facing challenges with its stock price recently downgraded to "Underperform" by Wolfe Research on November 20, 2025, at a price of $22.66 [1] - The current stock price is $22.36, reflecting a decrease of approximately 7.55% and significant volatility over the past year with a high of $48.92 and a low of $22.32 [2] - The company has secured a five-year loan of $1.5 billion from Ares Management to support its strategy for achieving up to 10% revenue growth in the coming year [3] - Active investor interest is indicated by a trading volume of 17.16 million shares despite the recent downgrade [4][5] Financial Position - Moderna's market capitalization is approximately $8.73 billion, indicating its size within the biotechnology sector [2] - The $1.5 billion loan is aimed at providing additional resources for investment in its pipeline and operational expansion [3] Market Activity - The stock has experienced a trading range between $22.32 and $24.91 today, with a drop of $1.83 [2] - Despite the downgrade, the decision to hold the stock suggests potential for future growth, which investors are closely monitoring [4]